Phase 3 Clinical Trials With Primary Completion Dates in January 2019
This is a list of Phase 3 trials with primary completion dates in January 2019 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| AXSM | Axsome Therapeutics, Inc. | 2019-01-01 | Phase 3 | NCT02741791 | A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Treatment Resistant Major Depressive Disorder |
| AXSM | Axsome Therapeutics, Inc. | 2019-01-01 | Phase 3 | NCT02504008 | CREATE-1: A Study to Assess the Efficacy and Safety of AXS-02 in Patients With CRPS-1 |
| CANF | Can-Fite Biopharma Ltd | 2019-01-01 | Phase 3 | NCT02647762 | CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis |
| EYEN | Eyenovia, Inc. | 2019-01-01 | Phase 3 | NCT03751631 | Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation |
| EYEN | Eyenovia, Inc. | 2019-01-01 | Phase 3 | NCT03751098 | Safety and Efficacy of Phenylephrine 2.5%-Tropicamide 1% Microdose Ophthalmic Solution for Pupil Dilation |
| GKOS | Glaukos Corporation | 2019-01-01 | Phase 3 | NCT01461278 | Multicenter Investigation of the Glaukos® Suprachoroidal Stent Model G3 In Conjunction With Cataract Surgery |
| JAZZ | Jazz Pharmaceuticals plc | 2019-01-01 | Phase 3 | NCT03030599 | A Study of the Efficacy and Safety of JZP-258 in Subjects With Narcolepsy With Cataplexy |
| LIVN | LivaNova PLC | 2019-01-01 | Phase 3 | NCT03279484 | Safety and Electrical Performances Evaluation of Navigo Leads Equipped With IS4 Connector |
| MNK | Mallinckrodt plc | 2019-01-01 | Phase 3 | NCT02321319 | Open-Label Safety and PK Study of ER Hydromorphone Tablets in Opioid-Tolerant Pediatric Chronic Pain Patients |
| OSMT | Osmotica Pharmaceuticals plc | 2019-01-01 | Phase 3 | NCT03290131 | A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS |
| PCRX | Pacira Pharmaceuticals, Inc. | 2019-01-01 | Phase 3 | NCT02740114 | Wound Infiltration With Liposomal Bupivacaine vs. Standard Wound Infiltration With Bupivacaine in Patient's Undergoing Open Gynecologic Surgery on an Enhanced Recovery Pathway |
| RARE | Ultragenyx Pharmaceutical Inc. | 2019-01-01 | Phase 3 | NCT02432144 | A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7 |
| RARE | Ultragenyx Pharmaceutical Inc. | 2019-01-01 | Phase 3 | NCT03581591 | Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets |